Drug DevelopmentPositive top-line phase 1 data for oral once-daily GLP-1R agonist CT-996 in people with obesity without diabetes shows 6.1% placebo-adjusted weight loss.
Earnings PotentialBetter than anticipated cost control results in a 5% upgrade to 2024 Core EPS and leads to a 7-10% upgrade to 2025-30 Core EPS.
Sales GrowthThree FDA approved drugs (Phesgo, Vabysmo, Hemlibra) and Diagnostics are expected to drive faster sales growth and greater operating leverage.